[go: up one dir, main page]

HRP20220929T3 - Sastav za inhalaciju koji sadrži aklidinij za liječenje astme - Google Patents

Sastav za inhalaciju koji sadrži aklidinij za liječenje astme

Info

Publication number
HRP20220929T3
HRP20220929T3 HRP20220929TT HRP20220929T HRP20220929T3 HR P20220929 T3 HRP20220929 T3 HR P20220929T3 HR P20220929T T HRP20220929T T HR P20220929TT HR P20220929 T HRP20220929 T HR P20220929T HR P20220929 T3 HRP20220929 T3 HR P20220929T3
Authority
HR
Croatia
Prior art keywords
aclidinium
pharmaceutical composition
use according
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HRP20220929TT
Other languages
English (en)
Inventor
Rosa Lamarca Casado
Gonzalo De Miquel Serra
Original Assignee
Almirall, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39645012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20220929(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall, S.A. filed Critical Almirall, S.A.
Publication of HRP20220929T3 publication Critical patent/HRP20220929T3/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (17)

1. Farmaceutski sastav koji sadrži aklidinij u obliku suhog praha farmaceutski prihvatljive soli u smjesi s farmaceutski prihvatljivim nosačem suhog praha, koji osigurava izmjerenu nominalnu dozu aklidinija ekvivalentnu 400 μg (plus/minus 10%) aklidinijev bromida za upotrebu inhalacijom u liječenju astme.
2. Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1, u obliku jednodozne formulacije suhog praha koja obuhvaća jednu izmjerenu nominalnu dozu aklidinija ekvivalentnu 400 mikrograma (plus/minus 10%) aklidinijev bromida.
3. Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1, u obliku višedozne formulacije suhog praha za primjenu u višedoznom uređaju za inhalaciju suhog praha kalibriranom da osigura izmjerenu nominalnu dozu aklidinija ekvivalentnu 400 μg (plus/minus 10%) aklidinijev bromida.
4. Farmaceutski sastav za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva gdje je (a) farmaceutski prihvatljiva sol aklidinija aklidinijev bromid, i/ili su (b) farmaceutski prihvatljiv nosač čestice laktoze.
5. Farmaceutski sastav za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva gdje je odnos mase aklidinija prema nosaču od 1:25 do 1:75.
6. Farmaceutski sastav za upotrebu prema patentnom zahtjevu 5, gdje je odnos mase aklidinija prema nosaču od 1:50 do 1:75.
7. Farmaceutski sastav za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, gdje je (a) prosječan promjer čestice aklidinija između 2–5 μm, i/ili (b) čestice nosača imaju d10 od 90–160 μm, d50 od 170–270 μm, i d90 od 290–400 μm.
8. Farmaceutski sastav za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, gdje farmaceutski sastav još obuhvaća djelotvornu količinu jednog ili više dodatnih aktivnih sredstava izabranih od β2-agonista, PDEIV inhibitora i kortikosteroida.
9. Farmaceutski sastav za upotrebu prema patentnom zahtjevu 8, gdje se dodatno aktivno sredstvo bira od (i) formoterola, salmeterola i budezonida, u slobodnom obliku ili u obliku farmaceutski prihvatljive soli, i (ii) flutikazon propionata.
10. Farmaceutski sastav za upotrebu prema patentnom zahtjevu 9, gdje je (a) dodatno aktivno sredstvo formoterolfumarat u količini od 5–25 μg po dozi, ili (b) dodatno aktivno sredstvo je formoterolfumarat u količini od 6 μg po dozi, ili (c) dodatno aktivno sredstvo je formoterolfumarat u količini od 12 μg po dozi.
11. Aklidinij u slobodnom obliku ili obliku farmaceutski prihvatljive soli za upotrebu u liječenju astme kod pacijenta kojem je potrebno takvo liječenje, pri čemu navedena upotreba obuhvaća davanje inhalacijom jednom ili dvaput dnevno u izmjerenoj nominalnoj dozi aklidinija ekvivalentnoj 400 μg (plus/minus 10%) aklidinijev bromida.
12. Aklidinij u slobodnom obliku ili obliku farmaceutski prihvatljive soli za upotrebu prema patentnom zahtjevu 11, pri čemu navedena upotreba obuhvaća davanje farmaceutskog sastava kako je definirano u bilo kojem od zahtjeva 1 do 10.
13. Aklidinij u slobodnom obliku ili obliku farmaceutski prihvatljive soli za upotrebu prema patentnom zahtjevu 11 ili 12, pri čemu navedena upotreba još obuhvaća davanje djelotvorne količine jednog ili više dodatnih aktivnih sredstava odabranih od β2-agonista, PDEIV inhibitora i kortikosteroida.
14. Aklidinij u slobodnom obliku ili obliku farmaceutski prihvatljive soli za upotrebu prema patentnom zahtjevu 13, gdje je dodatno aktivno sredstvo odabrano od (i) formoterola, salmeterola i budezonida, u slobodnom obliku ili u obliku farmaceutski prihvatljive soli, i (ii) flutikazon propionata.
15. Aklidinij u slobodnom obliku ili obliku farmaceutski prihvatljive soli za upotrebu prema patentnom zahtjevu 14, gdje je (a) dodatno aktivno sredstvo formoterolfumarat u količini od 5–25 μg po dozi, ili (b) dodatno aktivno sredstvo formoterolfumarat u količini od 6 μg po dozi, ili (c) dodatno aktivno sredstvo formoterolfumarat u količini od 12 μg po dozi.
16. Upotreba aklidinija u slobodnom obliku ili obliku farmaceutski prihvatljive soli u proizvodnji lijeka za liječenje astme kod pacijenta kojem je potrebno takvo liječenje, pri čemu navedena upotreba obuhvaća davanje inhalacijom jednom ili dvaput dnevno izmjerene nominalne doze aklidinija ekvivalentne 400 μg (plus/minus 10%) aklidinijev bromida.
17. Upotreba prema patentnom zahtjevu 16, gdje ta upotreba obuhvaća davanje farmaceutskog sastava kako je definirano u bilo kojem od patentnih zahtjeva 1 do 10.
HRP20220929TT 2008-03-13 2009-03-13 Sastav za inhalaciju koji sadrži aklidinij za liječenje astme HRP20220929T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08382010A EP2100599A1 (en) 2008-03-13 2008-03-13 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP15173011.6A EP2954891B1 (en) 2008-03-13 2009-03-13 Inhalation composition containing aclidinium for treatment of asthma

Publications (1)

Publication Number Publication Date
HRP20220929T3 true HRP20220929T3 (hr) 2022-10-28

Family

ID=39645012

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20220929TT HRP20220929T3 (hr) 2008-03-13 2009-03-13 Sastav za inhalaciju koji sadrži aklidinij za liječenje astme
HRP20220919TT HRP20220919T3 (hr) 2008-03-13 2009-03-13 Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća
HRP20151214TT HRP20151214T4 (hr) 2008-03-13 2009-03-13 Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20220919TT HRP20220919T3 (hr) 2008-03-13 2009-03-13 Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća
HRP20151214TT HRP20151214T4 (hr) 2008-03-13 2009-03-13 Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti

Country Status (37)

Country Link
US (3) US20110020412A1 (hr)
EP (5) EP2100599A1 (hr)
JP (3) JP2011513451A (hr)
KR (3) KR20200054329A (hr)
CN (2) CN104473911A (hr)
AR (1) AR070835A1 (hr)
AU (1) AU2009224895B9 (hr)
BR (1) BRPI0905775B1 (hr)
CA (1) CA2716724C (hr)
CL (1) CL2009000602A1 (hr)
CO (1) CO6290636A2 (hr)
CY (1) CY1116926T1 (hr)
DK (3) DK2265257T4 (hr)
EC (1) ECSP10010300A (hr)
ES (3) ES2914674T3 (hr)
FI (1) FI2265257T4 (hr)
HK (1) HK1145815A1 (hr)
HR (3) HRP20220929T3 (hr)
HU (3) HUE059020T2 (hr)
IL (3) IL271132B2 (hr)
LT (2) LT2954889T (hr)
ME (1) ME02286B (hr)
MX (2) MX368774B (hr)
MY (1) MY177027A (hr)
NZ (1) NZ585857A (hr)
PE (3) PE20091672A1 (hr)
PL (3) PL2954891T3 (hr)
PT (3) PT2954889T (hr)
RS (3) RS54241B2 (hr)
RU (3) RU2608713C3 (hr)
SG (1) SG188825A1 (hr)
SI (3) SI2954891T1 (hr)
TW (1) TWI439296B (hr)
UA (1) UA101652C2 (hr)
UY (1) UY31687A1 (hr)
WO (1) WO2009112274A2 (hr)
ZA (1) ZA201003900B (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) * 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) * 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
EA201590030A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
US20150202148A1 (en) * 2012-07-05 2015-07-23 Arven llac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
SI2931275T1 (sl) 2012-12-17 2022-07-29 Almirall, S.A. Aklidinij za uporabo v povečanju telesne aktivnosti v vsakdanjem življenju pacienta, ki ima kronično obstruktivno pljučno bolezen
EP2991626A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
EP2923702A1 (en) * 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
ES2682105T3 (es) 2014-05-12 2018-09-18 Verona Pharma Plc Nuevo tratamiento
CZ2015257A3 (cs) * 2015-04-16 2016-10-26 Zentiva, K.S. Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu
CN107823193B (zh) * 2017-11-16 2021-02-05 广州迈达康医药科技有限公司 一种阿地溴铵吸入型粉雾剂及其制备方法

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
ES2161211T3 (es) 1990-09-06 2001-12-01 Pfizer Broncodilatadores antimuscarinicos.
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
EP0503031B1 (en) 1990-09-26 1998-04-01 Pharmachemie B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
US5865834A (en) 1991-12-13 1999-02-02 Mcguire; David A. Coring reamer
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
NZ259192A (en) 1992-12-09 1997-05-26 Boehringer Ingelheim Pharma Aerosol medicament comprising water-sensitive or solvent-sensitive active agent, hfc propellant stabilised by addition of (in)organic acid
RU2111020C1 (ru) 1992-12-18 1998-05-20 Шеринг Корпорейшн Ингалятор для порошковых лекарств
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5569447A (en) 1994-04-19 1996-10-29 The United States Of America Represented By The Secretary Department Of Health And Human Services Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
EP0772656B1 (en) 1994-07-29 2001-03-21 Minnesota Mining And Manufacturing Company Acrylic syrup curable to a crosslinked viscoelastomeric material
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ES2206572T3 (es) 1995-04-14 2004-05-16 Smithkline Beecham Corporation Inhalador de dosis medida para salmeterol.
KR100269060B1 (ko) 1995-06-21 2000-11-01 패르난대즈 마르케스 일체된 미터링 장치를 가진 약제 분말 카트리지 및 분말 약흡입기
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
RS49977B (sr) 1998-06-18 2008-09-29 Boehringer Ingelheim Pharmaceuticals Inc., Farmaceutske formulacije za aerosolove sa dve ili više aktivnih supstanci
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
PT1102579E (pt) 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19912434B4 (de) * 1999-03-19 2013-10-24 Roche Diagnostics Gmbh Infusionsgerät, Kathetereinrichtung und Katheterkopf
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
CA2398199A1 (en) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
GEP20043385B (en) 2000-01-31 2004-04-13 Pfizer Prod Inc Pyrimidine Carboxamides Useful as Inhibitors of PDE4 Isozymes, Pharmaceutical Compositions Containing the Same
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
UA73986C2 (uk) 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
AU2001285431A1 (en) 2000-08-10 2002-02-18 Eharmony.Com, Inc Method and system for identifying people who are likely to have a successful relationship
US6852728B2 (en) 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
JP2004512359A (ja) * 2000-10-31 2004-04-22 ベーリンガー　インゲルハイム　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　ウント　コンパニー　コマンディトゲゼルシャフト 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
SI1345937T1 (sl) 2000-12-22 2006-02-28 Almirall Prodesfarma Ag Derivati kinulidinkarbamata in njihova uporaba kot M3 antagonisti
CN1250545C (zh) 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
DE10104370A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10104367A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US20020189610A1 (en) 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
DE60216588T2 (de) 2001-05-25 2007-09-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
WO2002096463A1 (en) 2001-05-25 2002-12-05 Pfizer Inc. A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
JP2005504076A (ja) 2001-09-14 2005-02-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な吸入用医薬組成物
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US6790856B2 (en) 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
SI3494995T1 (sl) 2002-03-01 2020-08-31 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
US7094788B2 (en) 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
RU2316318C2 (ru) 2002-05-17 2008-02-10 Новартис Аг Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006508996A (ja) 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト 悪液質の治療における使用のための、ｐｄｅ４及びｐｄｅ３／４インヒビター
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
WO2004084896A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
WO2004084897A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
AU2004262902B2 (en) 2003-07-29 2009-07-30 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic
JP2007500150A (ja) † 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とステロイドとの併用剤及び吸入により呼吸障害を治療するためのその使用
US20050026887A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
US20050026886A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
JP2007500149A (ja) 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患を治療するためのｐｄｅｉｖ阻害剤と抗コリン作用剤を含む薬剤
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ATE541570T1 (de) 2004-02-06 2012-02-15 Meda Pharma Gmbh & Co Kg Kombination von anticholinergika und hemmern von phosphodiesterase typ 4 zur behandlung von atemwegserkrankungen
ATE399027T1 (de) 2004-02-06 2008-07-15 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
JP4819699B2 (ja) 2004-02-06 2011-11-24 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 喘息及びｃｏｐｄの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
WO2005115465A1 (en) 2004-05-31 2005-12-08 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20090298802A1 (en) 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
GB0702457D0 (en) † 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
US20100063016A1 (en) † 2007-02-19 2010-03-11 Cipla Limited Pharmaceutical Combinations
DK2120936T3 (da) 2007-02-21 2011-09-26 Almirall Sa Nye fremgangsmåder
EP2100599A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) † 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
SI2931275T1 (sl) 2012-12-17 2022-07-29 Almirall, S.A. Aklidinij za uporabo v povečanju telesne aktivnosti v vsakdanjem življenju pacienta, ki ima kronično obstruktivno pljučno bolezen
WO2014096553A1 (en) 2012-12-21 2014-06-26 Intellipocket Oy Generating a customized application

Also Published As

Publication number Publication date
HRP20220919T3 (hr) 2022-10-28
IL271132A (en) 2020-01-30
ES2551307T3 (es) 2015-11-18
US20110020412A1 (en) 2011-01-27
US20180303806A1 (en) 2018-10-25
CO6290636A2 (es) 2011-06-20
SI2954891T1 (sl) 2022-07-29
LT2954891T (lt) 2022-06-10
AU2009224895A1 (en) 2009-09-17
EP2954889B1 (en) 2022-05-04
IL206354A0 (en) 2010-12-30
US11000517B2 (en) 2021-05-11
WO2009112274A2 (en) 2009-09-17
HRP20151214T4 (hr) 2024-01-05
TW200938232A (en) 2009-09-16
KR20200054329A (ko) 2020-05-19
EP2954890A1 (en) 2015-12-16
DK2954889T3 (da) 2022-06-07
RU2019100425A3 (hr) 2020-07-13
EP2954891A1 (en) 2015-12-16
RU2608713C2 (ru) 2017-01-23
BRPI0905775B1 (pt) 2021-07-27
PL2954891T3 (pl) 2022-09-26
JP2014139233A (ja) 2014-07-31
CA2716724A1 (en) 2009-09-17
CN102083416A (zh) 2011-06-01
SI2265257T2 (sl) 2023-12-29
EP2954891B1 (en) 2022-05-04
SI2265257T1 (sl) 2016-02-29
JP6170460B2 (ja) 2017-07-26
PT2954891T (pt) 2022-05-19
SI2954889T1 (sl) 2022-07-29
CY1116926T1 (el) 2017-04-05
SG188825A1 (en) 2013-04-30
US20130189317A1 (en) 2013-07-25
DK2954891T3 (da) 2022-06-13
JP2011513451A (ja) 2011-04-28
LT2954889T (lt) 2022-06-10
DK2265257T4 (da) 2023-12-18
AR070835A1 (es) 2010-05-05
RS54241B1 (en) 2015-12-31
CN104473911A (zh) 2015-04-01
US10085974B2 (en) 2018-10-02
EP2265257A2 (en) 2010-12-29
IL249072A0 (en) 2017-01-31
RS54241B2 (sr) 2024-02-29
PL2265257T5 (pl) 2024-06-10
AU2009224895B2 (en) 2015-07-02
PT2954889T (pt) 2022-05-19
DK2265257T3 (en) 2015-11-23
ECSP10010300A (es) 2010-07-30
ES2551307T5 (es) 2024-04-05
HUE059020T2 (hu) 2022-09-28
PL2265257T3 (pl) 2016-01-29
WO2009112274A3 (en) 2010-09-02
KR20100126322A (ko) 2010-12-01
ZA201003900B (en) 2011-04-28
BRPI0905775A2 (pt) 2018-05-22
PT2265257E (pt) 2015-11-13
RS63399B1 (sr) 2022-08-31
PL2954889T3 (pl) 2022-11-07
ES2916831T3 (es) 2022-07-06
TWI439296B (zh) 2014-06-01
EP2265257B2 (en) 2023-10-25
RU2019100425A (ru) 2020-07-13
UA101652C2 (uk) 2013-04-25
RU2014140674A (ru) 2016-04-27
IL271132B2 (en) 2025-03-01
JP2016130248A (ja) 2016-07-21
RS63398B1 (sr) 2022-08-31
PE20091672A1 (es) 2009-11-04
CL2009000602A1 (es) 2010-03-12
PE20141036A1 (es) 2014-08-27
EP2954889A1 (en) 2015-12-16
FI2265257T4 (fi) 2023-11-22
HUE059019T2 (hu) 2022-09-28
KR20180125055A (ko) 2018-11-21
HK1145815A1 (zh) 2011-05-06
EP2265257B1 (en) 2015-08-12
HUE027726T2 (en) 2016-11-28
MX2010008235A (es) 2010-08-10
ME02286B (me) 2016-02-20
RU2010141333A (ru) 2012-04-20
PE20190406A1 (es) 2019-03-14
AU2009224895B9 (en) 2015-07-30
HRP20151214T1 (hr) 2015-12-18
UY31687A1 (es) 2009-08-31
MX368774B (es) 2019-10-16
RU2608713C3 (ru) 2018-09-10
MY177027A (en) 2020-09-02
EP2100599A1 (en) 2009-09-16
IL271132B1 (en) 2024-11-01
CA2716724C (en) 2016-04-26
NZ585857A (en) 2012-09-28
ES2914674T3 (es) 2022-06-15

Similar Documents

Publication Publication Date Title
HRP20220929T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje astme
ME02318B (me) Jedinjenje za inhalaciju koje sadrži aklidinijum za liječenje astme
WO2007123955A3 (en) Stable hydroalcoholic oral spray formulations and methods
JP2012082229A (ja) 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
RU2013142268A (ru) Фармацевтическая композиция
JP2011520911A5 (hr)
JP2010132695A5 (hr)
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
JP2015519356A5 (hr)
WO2021229514A1 (en) Pharmaceutical ivermectin compositions
WO2012107765A3 (en) Particle formulation
KR20220158030A (ko) 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
Hassoun et al. Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers
KR20230038228A (ko) 글루코코르티코이드 절약제
RS54874B1 (sr) Upotreba kompozicije koja obuhvata formoterol i beklometazon dipropionat za tretman egzacerbacije astme
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2012042197A2 (en) Low dose pharmaceutical composition
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
HRP20221034T1 (hr) Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
JP2007518817A5 (hr)
JP2013522295A5 (hr)